跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
TRI-JORDYNA 28
Authorized
STANDARD
TRI-JORDYNA 28
glenmark pharmaceuticals canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
03b1a9ebac6bb5bd
Company
glenmark pharmaceuticals canada inc.
Type
Standard
Approval Details
Approval Id
03b1a9ebac6bb5bd
Drug Approval Canada Name
TRI-JORDYNA 28
Product Name
TRI-JORDYNA 28
Status
Marketed
Status Date
2020-03-18
Original Market Date
2020-03-18
Din
02486318
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:12.00
Atc Original
G03AB09 NORGESTIMATE AND ETHINYLESTRADIOL
Atc Name
g 03 ab 09
Aig Number
0636783002
Company Name
glenmark pharmaceuticals canada inc.
Company Address
1600 Steeles Ave. W., Suite 407, Concord, Ontario, Canada, L4K 4M2
Active Ingredients
ETHINYL ESTRADIOL
0.035 MG
NORGESTIMATE
0.18 MG
NORGESTIMATE
0.215 MG
NORGESTIMATE
0.25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
03b1a9ebac6bb5bd
Type
Standard
Back to Health Canada Approvals
TRI-JORDYNA 28 - Health Canada Drug Approval Details